BORTEZOMIB TEVA 1 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

BORTEZOMIB

Disponible depuis:

ABIC MARKETING LTD, ISRAEL

Code ATC:

L01XX32

forme pharmaceutique:

POWDER FOR SOLUTION FOR INJECTION

Composition:

BORTEZOMIB 1 MG

Mode d'administration:

I.V

Type d'ordonnance:

Required

Fabriqué par:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Domaine thérapeutique:

BORTEZOMIB

indications thérapeutiques:

Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

Date de l'autorisation:

2017-07-04